Reneo Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) is a clinical-stage biotechnology company focused on developing therapies for rare genetic mitochondrial diseases. The company advances novel product candidates targeting mitochondrial dysfunction, including REN001, a peroxisome proliferator-activated receptor delta agonist in Phase 3 trials for primary mitochondrial myopathy; REN004, an investigational therapy for rare monogenic muscle diseases; and other pipeline assets aimed at addressing unmet needs in neuromuscular and metabolic disorders. Reneo offers research and development services in drug discovery, preclinical studies, and clinical trial management for mitochondrial-targeted treatments; it does not currently market any commercial products. Founded in 2008 and headquartered in Irvine, California, the company operates primarily in the United States with clinical trials conducted globally, targeting patients with rare mitochondrial disorders through partnerships with academic institutions and contract research organizations. In recent developments, Reneo completed a strategic pipeline reprioritization in 2024, discontinuing its Phase 2b LION101 program for primary mitochondrial myopathy to focus resources on REN001's pivotal trial and earlier-stage assets; the company also raised approximately $15 million through a registered direct offering in late 2024 to support ongoing operations and clinical advancements.
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHM
Shareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKure
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences